Literature DB >> 19591571

Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments.

Michael G Hudgens1, Peter B Gilbert, John R Mascola, Chih-Da Wu, Dan H Barouch, Steven G Self.   

Abstract

Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge experiments performed in nonhuman primates to detect the effect of a candidate human immunodeficiency virus vaccine. The effect of various design parameters on power was explored. Results of simulation studies indicate that repeated low-dose challenge studies with a total sample of size 50 (25 animals/arm) typically provide adequate power to detect a 50% reduction in the per-exposure probability of infection resulting from vaccination. Power generally increases with the maximum number of allowable challenges per animal, the per-exposure risk of infection in control animals, and the proportion of animals susceptible to infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591571      PMCID: PMC2754821          DOI: 10.1086/600891

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.

Authors:  Dennis Ellenberger; Ronald A Otten; Bin Li; Michael Aidoo; I Vanessa Rodriguez; Carlos A Sariol; Melween Martinez; Michael Monsour; Linda Wyatt; Michael G Hudgens; Edmundo Kraiselburd; Bernard Moss; Harriet Robinson; Thomas Folks; Salvatore Butera
Journal:  Virology       Date:  2006-05-24       Impact factor: 3.616

Review 2.  A strategy for accelerating the development of preventive AIDS vaccines.

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Patricia Fast; Wayne Koff
Journal:  AIDS       Date:  2007-11-12       Impact factor: 4.177

3.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

4.  The large sample distribution of the weighted log rank statistic under general local alternatives.

Authors:  M Ewell; J G Ibrahim
Journal:  Lifetime Data Anal       Date:  1997       Impact factor: 1.588

5.  Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.

Authors:  Shambavi Subbarao; Ronald A Otten; Artur Ramos; Caryn Kim; Eddie Jackson; Michael Monsour; Debra R Adams; Sheila Bashirian; Jeffrey Johnson; Vincent Soriano; Ana Rendon; Michael G Hudgens; Salvatore Butera; Robert Janssen; Lynn Paxton; Alan E Greenberg; Thomas M Folks
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

6.  Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates.

Authors:  Ron A Otten; Debra R Adams; Caryn N Kim; Eddie Jackson; Jennifer K Pullium; Kemba Lee; Lisa A Grohskopf; Michael Monsour; Sal Butera; Thomas M Folks
Journal:  J Infect Dis       Date:  2004-12-09       Impact factor: 5.226

7.  Assessing vaccine effects in repeated low-dose challenge experiments.

Authors:  Michael G Hudgens; Peter B Gilbert
Journal:  Biometrics       Date:  2009-12       Impact factor: 2.571

8.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

9.  The use of nonhuman primate models in HIV vaccine development.

Authors:  Cecilia Morgan; Marta Marthas; Christopher Miller; Ann Duerr; Cecilia Cheng-Mayer; Ronald Desrosiers; Jorge Flores; Nancy Haigwood; Shiu-Lok Hu; R Paul Johnson; Jeffrey Lifson; David Montefiori; John Moore; Marjorie Robert-Guroff; Harriet Robinson; Steven Self; Lawrence Corey
Journal:  PLoS Med       Date:  2008-08-12       Impact factor: 11.069

10.  Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

Authors:  J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  27 in total

Review 1.  The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.

Authors:  Richard A Koup; Barney S Graham; Daniel C Douek
Journal:  Nat Rev Immunol       Date:  2010-12-17       Impact factor: 53.106

2.  Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.

Authors:  Nicola Winstone; Aaron J Wilson; Gavin Morrow; Cesar Boggiano; Maria J Chiuchiolo; Mary Lopez; Marina Kemelman; Arielle A Ginsberg; Karl Mullen; John W Coleman; Chih-Da Wu; Sandeep Narpala; Ian Ouellette; Hansi J Dean; Feng Lin; Niranjan Y Sardesai; Holly Cassamasa; Dawn McBride; Barbara K Felber; George N Pavlakis; Alan Schultz; Michael G Hudgens; C Richter King; Timothy J Zamb; Christopher L Parks; Adrian B McDermott
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

3.  A discrete-time survival model with random effects for designing and analyzing repeated low-dose challenge experiments.

Authors:  Chaeryon Kang; Ying Huang; Christopher J Miller
Journal:  Biostatistics       Date:  2014-09-03       Impact factor: 5.899

4.  A method to address between-subject heterogeneity for identification of principal surrogate markers in repeated low-dose challenge HIV vaccine studies.

Authors:  Andrew J Spieker; Ying Huang
Journal:  Stat Med       Date:  2017-07-31       Impact factor: 2.373

5.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Authors:  Monica Vaccari; Shari N Gordon; Slim Fourati; Luca Schifanella; Namal P M Liyanage; Mark Cameron; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Erik Billings; Mangala Rao; Amy W Chung; Karen G Dowell; Chris Bailey-Kellogg; Eric P Brown; Margaret E Ackerman; Diego A Vargas-Inchaustegui; Stephen Whitney; Melvin N Doster; Nicolo Binello; Poonam Pegu; David C Montefiori; Kathryn Foulds; David S Quinn; Mitzi Donaldson; Frank Liang; Karin Loré; Mario Roederer; Richard A Koup; Adrian McDermott; Zhong-Min Ma; Christopher J Miller; Tran B Phan; Donald N Forthal; Matthew Blackburn; Francesca Caccuri; Massimiliano Bissa; Guido Ferrari; Vaniambadi Kalyanaraman; Maria G Ferrari; DeVon Thompson; Marjorie Robert-Guroff; Silvia Ratto-Kim; Jerome H Kim; Nelson L Michael; Sanjay Phogat; Susan W Barnett; Jim Tartaglia; David Venzon; Donald M Stablein; Galit Alter; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

6.  Analysis of repeated low-dose challenge studies.

Authors:  Tracy L Nolen; Michael G Hudgens; Pranab K Senb; Gary G Koch
Journal:  Stat Med       Date:  2015-03-09       Impact factor: 2.373

7.  Surrogates of protection in repeated low-dose challenge experiments.

Authors:  Dustin M Long; Michael G Hudgens; Chih-Da Wu
Journal:  Stat Med       Date:  2015-01-28       Impact factor: 2.373

8.  Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Authors:  Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

9.  Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection.

Authors:  Hongzhao Li; Robert W Omange; Binhua Liang; Nikki Toledo; Yan Hai; Lewis R Liu; Dane Schalk; Jose Crecente-Campo; Tamara G Dacoba; Andrew B Lambe; So-Yon Lim; Lin Li; Mohammad Abul Kashem; Yanmin Wan; Jorge F Correia-Pinto; Michael S Seaman; Xiao Qing Liu; Robert F Balshaw; Qingsheng Li; Nancy Schultz-Darken; Maria J Alonso; Francis A Plummer; James B Whitney; Ma Luo
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

10.  Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.

Authors:  Kara Jensen; Rafiq Nabi; Koen K A Van Rompay; Spencer Robichaux; Jeffrey D Lifson; Michael Piatak; William R Jacobs; Glenn Fennelly; Don Canfield; Katie R Mollan; Michael G Hudgens; Michelle H Larsen; Angela M Amedee; Pamela A Kozlowski; Kristina De Paris
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.